TRK 950
Alternative Names: TRK-950Latest Information Update: 28 May 2025
At a glance
- Originator Toray
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Gastric cancer; Oesophageal cancer; Solid tumours
Most Recent Events
- 28 May 2025 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease) in France (IV, Infusion)
- 28 May 2025 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease) in USA (IV, Infusion)
- 11 Feb 2025 Bolt Biotherapeutics worldwide co-development collaboration with Toray Industries for TRK 950